Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ptgx · stock forecast · 26 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 26 Wall Street analysts in the past 3 months
Buy
26 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$121
Consensus
$115
+19.0% upside
Low
$108
Median: $117 · Last Close: $97.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$115.40
19.0% upside
High Target
$121
24.7%
Low Target
$108
11.3%
Current Price
$97.00
as of today
Based on analyst price targets, the PTGX stock price prediction for the next 12 months ranges from $108 to $121. The consensus PTGX price forecast of $115.40 implies 19.0% upside from the current price of $97.00.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $95.16 | ↓ 1.90% |
1-day model range: $94.63–$95.69. Peak: $95.69 (-1.90%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $153 | +57.6% |
| 2028 | $206 | +112.0% |
| 2029 | $248 | +155.9% |
| 2030 | $279 | +187.7% |
| 2031 | — | +209.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PTGX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-06 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-05-06 | Wedbush | Maintains | Outperform→Outperform |
| 2026-04-15 | Truist Securities | Maintains | Buy→Buy |
| 2026-04-07 | Clear Street | Maintains | Buy→Buy |
| 2026-03-19 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-03-19 | Citigroup | Maintains | Buy→Buy |
| 2026-03-19 | Barclays | Maintains | Overweight→Overweight |
| 2026-03-19 | Leerink Partners | Maintains | Outperform→Outperform |
| 2026-03-03 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2026-02-26 | Citizens | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Protagonist Therapeutics, Inc. (PTGX) stock. Of the recent 115 rating actions, 4 were upgrades and 2 were downgrades. 26 analysts currently cover PTGX.
Analyst Recommendation Trends
PTGX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$504M
↑ 78.2% YoY
Revenue Next Year
$144M
↓ 71.4% YoY
EPS This Year
$4.03
EPS Next Year
$-0.97
↓ 124.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast PTGX EPS of $4.03 for the current fiscal year, based on estimates from 8 analysts. The PTGX revenue forecast is $504M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PTGX stock forecast is supported by two independent data sources: analyst consensus ratings from 26 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PTGX price target is $115.40 (+19.0% upside), with an analyst consensus of Buy.
The PTGX short-term stock prediction for tomorrow is $95.16 (-1.90%). The PTGX stock price prediction for 2027 estimates an average of $153. The PTGX stock prediction for 2030 projects a range of $262–$296.
Protagonist Therapeutics, Inc. trades on NASDAQ under the ticker PTGX. The PTGX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 96% of covering analysts.
Frequently asked questions
PTGX forecast · 8 questionsAccording to 26 Wall Street analysts, the average 12-month PTGX price target is $115.40, with a high forecast of $121.00 and a low of $108.00. The median price target is shown in the chart above when available. This implies +19.0% potential upside from the current price of $97.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.